Neonatal factors associated with HIV long term non-progressors in a cohort of vertically infected children in Rio de Janeiro, brazil ("Peixe" project)

Brazilian Journal of Infectious Diseases

Volumn 13, Issue 4, 2009, Pages 276-279

  Hofer, Cristina B ^a   Oliveira, Ricardo Hugo ^a   Machado, Elizabeth S ^a   Pala, Alessandra ^a   Evangelista, Lúcia ^a   Fernandes, Iraina ^a   Abreu, Thalita F ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Antiretroviral therapy; Brazil; Children; HIV; Long term non progressors

Indexed keywords

CD4 ANTIGEN; ZIDOVUDINE;

ARTICLE; BRAZIL; CHILD; COHORT ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INFANT; INTRAUTERINE INFECTION; MAJOR CLINICAL STUDY; MALE; NEWBORN; NEWBORN PERIOD; PRESCHOOL CHILD;

ANTI-HIV AGENTS; BRAZIL; CD4-POSITIVE T-LYMPHOCYTES; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; PROSPECTIVE STUDIES; VIRAL LOAD;

EID: 77949856819     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702009000400007     Document Type: Article

References (9)

1. European Collaborative Study. Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life. Pediatrics 2001;108:116-22.
2. Scott GB, Hutto C, Makuch RW, Mastrucci MT, O'Connor T, Mitchell CD, et al. Survival in children with perinatally acquired human immunodeficiency virus type 1 infection. N Engl J Med 1989; 321:1791-6.
3. Foster C. & Lyall EG. Children with HIV: improved mortality and morbidity with combination antiretroviral therapy. Current Opinion in Infectious Diseases 2005; 18:253-9.
4. Walker AS. Doerholt K. Sharland M. Gibb DM. Collaborative HIV Paediatric Study (CHIPS) Steering Committee. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS 2004; 18:1915-24.
5. Aboulker JP. Babiker A. Chaix ML. Compagnucci A. Darbyshire J. Debre M. Faye A. Giaquinto C. Gibb DM. Harper L. Saidi Y. Walker AS. Paediatric European Network for Treatment of AIDS. Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS 2004; 18:237-45.
6. Abrams EJ, Thomas P, Weedon J, Bertolli J, Bornschegle K, Cervia J, et al. Aging cohort of perinatally human immunodeficiency virus-infected children in New York City. Pediatr Infect Dis J 2001; 20:511-7.
7. Rich KC. Fowler MG. Mofenson LM. Abboud R. Pitt J. Diaz C. Hanson IC. Cooper E. Mendez H. Maternal and infant factors predicting disease progression in human immunodeficiency virus type 1-infected infants. Women and Infants Transmission Study Group. Pediatrics 2000; 105:e8.
8. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection - Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, 2005. In: http:/ /aidsinfo.nih.gov/ContentFiles/ PediatricGuidelines.pdf.
9. Guia de Tratamento Clínico da Iinfecção pelo HIV em Pediatria - Ministério da Saúde do Brasil, 2006.In:http:// www.aids.gov.br/ d a t a / d o c u m e n t s / s t o r e d D o c u m e n t s / consenso-crianca-versao-preliminar-25ago06.pdf.